DeepGB-TB: A Risk-Balanced Cross-Attention Gradient-Boosted Convolutional Network for Rapid, Interpretable Tuberculosis Screening
Abstract
Large-scale tuberculosis (TB) screening is limited by the high cost and operational complexity of traditional diagnostics, creating a need for artificial-intelligence solutions. We propose DeepGB-TB, a non-invasive system that instantly assigns TB risk scores using only cough audio and basic demographic data. The model couples a lightweight one-dimensional convolutional neural network for audio processing with a gradient-boosted decision tree for tabular features. Its principal innovation is a Cross-Modal Bidirectional Cross-Attention module (CM-BCA) that iteratively exchanges salient cues between modalities, emulating the way clinicians integrate symptoms and risk factors. To meet the clinical priority of minimizing missed cases, we design a Tuberculosis Risk-Balanced Loss (TRBL) that places stronger penalties on false-negative predictions, thereby reducing high-risk misclassifications. DeepGB-TB is evaluated on a diverse dataset of 1,105 patients collected across seven countries, achieving an AUROC of 0.903 and an F1-score of 0.851, representing a new state of the art. Its computational efficiency enables real-time, offline inference directly on common mobile devices, making it ideal for low-resource settings. Importantly, the system produces clinically validated explanations that promote trust and adoption by frontline health workers. By coupling AI innovation with public-health requirements for speed, affordability, and reliability, DeepGB-TB offers a tool for advancing global TB control.
Fields of Study & Subjects
COVID-19 diagnosis using AI
Tuberculosis Research and Epidemiology
Phonocardiography and Auscultation Techniques
Publication details
- Journal / source
- Proceedings of the AAAI Conference on Artificial Intelligence
- Publisher
- Association for the Advancement of Artificial Intelligence (AAAI)
- Volume
- 40
- Issue
- 46
- Pages
- 38989–38997
- Publication date
- 14 March 2026
- Language
- EN